Community mobility assessment for adolescents with an acquired brain injury: preliminary inter-rater reliability study.

BACKGROUND: The Community Mobility Assessment (CMA) is an observational assessment that evaluates safety of an adolescent with an acquired brain injury (ABI) during a community outing. It consists of a 3-point level of accomplishment scale for 40 functional items, divided into two components (physical and cognitive). The CMA identifies areas of strength and weakness and facilitates development of compensating strategies. This study was undertaken to determine how reliably therapists rate a client's performance using the CMA on a community outing. PARTICIPANTS: Eight adolescents between the ages of 12 and 18 participated. All had an ABI and were involved in rehabilitation either as a day-patient or inpatient. METHODS: Each teen was independently evaluated by one expert rater and one of two student raters (A or B), using the CMA during a standard 2-h community outing. ANALYSIS: Descriptive statistics were computed for physical and cognitive component summary scores. Inter-rater reliability analyses used weighted Kappa statistics. A minimum Kappa score >0.70 was hypothesized a priori to indicate good reliability. RESULTS: The mean score for the physical component = 92% (min = 82%, max = 100%), and for the cognitive component = 77% (min = 58%, max = 97%). Minimum weighted Kappa scores for the two rater pairings were 0.80 for the physical component and 0.70 for the cognitive component. CONCLUSIONS: An acceptable Kappa score was reached for both components, indicating that with appropriate rater training, the CMA has good inter-rater reliability. Construct validity and responsiveness to change over a clinically meaningful follow-up period should now be evaluated.

Positron emission tomography findings in obstructive sleep apnea patients with residual sleepiness treated with continuous positive airway pressure.

Despite sufficient continuous positive airway pressure (CPAP) therapy, some patients with the obstructive sleep apnea syndrome (OSAS) still suffer from excessive daytime sleepiness (EDS). In some of them, no cause of the persistence of EDS can be found. Brain damage due to nocturnal hypoxemia is a potential cause for this unclear persistent sleepiness (UPS). This study was done to evaluate this hypothesis. Patients with UPS were identified among the OSAS patients, who came for a CPAP therapy checkup to our sleep laboratory. UPS was recognized when no explanation for persistent EDS could be yielded by standard diagnostic procedures. Out of 167 patients under CPAP therapy 13 had UPS. To investigate the brain morphology, positron emission tomography (PET) scanning with the tracer fluorine-18 fluorodeoxyglucose (FDG), called FDG-PET, were performed in 7 of the UPS patients. Abnormal PET findings were concentrated in frontal area (found in 4 patients). The frontal abnormality seems to distinguish the OSAS patients with UPS from the whole OSAS population, examined in previous studies.

Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR).

OBJECTIVE: To assess the efficacy and safety of the dopamine agonist cabergoline in the treatment of patients with idiopathic restless legs syndrome (CATOR study). METHODS: Patients with moderate to severe restless legs syndrome (RLS) were randomly assigned to cabergoline (single evening dose: 2 mg) or placebo and treated for 5 weeks in a double-blind, multicenter polysomnography (PSG) trial. The primary efficacy measures were the periodic leg movements during sleep arousal index (PLMS-AI) and sleep efficiency. These and further PSG variables were monitored by centrally evaluated PSG. Severity of RLS was assessed using the International RLS Study Group Severity Scale (IRLS), the RLS-6 scales, the Sleep Questionnaire Form A (SF-A; quality of sleep), and the Quality of Life for RLS questionnaire. RESULTS: Forty-three patients were treated and 40 patients were evaluated with PSG (age 56 +/- 10 years, 73% women). Cabergoline was superior to placebo in terms of the PLMS-AI (-17.7 +/- 16.4 vs -4.5 +/- 20.0 placebo; p = 0.0024), sleep efficiency (+6.2 +/- 13.9% vs +3.3 +/- 11.7%; p = 0.0443), PLMS index (p = 0.0014), PLM index (p = 0.0012), and total sleep time (p = 0.0443). Improvements in IRLS total score (-23.7 +/- 11.2 vs -7.9 +/- 11.0 placebo; p = 0.0002), RLS-6 severity scales during the night (p = 0.0010) and during the day (p = 0.0018), Clinical Global Impressions severity item (p = 0.0003), sleep quality (p = 0.0180), SF-A sleep quality (p = 0.0371), and QoL-RLS (p = 0.0247) were larger in patients treated with cabergoline compared with the placebo group. Adverse events were only mild and well-known side effects of dopamine agonists. CONCLUSION: Single-evening cabergoline is an efficacious and well-tolerated short-term therapy for sensorimotor symptoms of restless legs syndrome and associated sleep disturbances.

Outcomes of CPAP treatment in a sleep laboratory specialized in neuropsychiatry.

The rapidly increasing number of sleep laboratories implicates their specialization into various fields of sleep medicine. In our sleep laboratory that specializes in neuropsychiatry, patients with the symptoms typical for the obstructive sleep apnea/hypopnea syndrome (OSAHS) were routinely redirected to a local respiratory clinic. Some patients, however, admitted to our center for other reasons revealed OSAHS in nocturnal polysomnography. The purpose of this retrospective study was to assess the outcome of CPAP in treating the sleepiness in this group of patients. Our material consisted of 36 patients who started CPAP therapy due to OSAHS diagnosed in our laboratory in the year 2000 and who came for a routine checkup in 2001. The sleepiness was assessed by using the Epworth Sleepiness Scale (ESS). After CPAP, the mean group ESS score decreased from 10.9 +/-4.4 to 8.5 +/-4.3 points (P<0.01). Some patients showed, however, persisting excessive sleepiness (PTS) after CPAP, defined as ESS >or=12. We overviewed the documentation of those patients in search for the possible causes of PTS. We identified the following causes: narcolepsy - 1 patient, insufficient CPAP pressure - 1 patient, low CPAP compliance, fewer than 2 h/night, - 2 patients. In 5 other patients we found CPAP compliance to be between 2.0 and 4.5 h/night, which is less likely to be the cause of PTS. In 1 patient no cause was identified. Our patients showed relatively mild sleepiness before CPAP and only a slight improvement under CPAP. The CPAP noncompliance seems the most prevailing reason for CPAP failure, but in some patients the cause of PTS could not be unraveled by using standard diagnostic tools and some additional measures are to be employed to resolve the issue.

Spectral composition of NREM sleep in healthy subjects with moderately increased daytime sleepiness.

OBJECTIVE: This study addressed the relationship between daytime sleepiness and spectral composition of the preceding NREM sleep. METHODS: Nineteen healthy volunteers (mean age: 36.5 years; SD: 10.1) underwent polysomnography during two consecutive nights and the multiple sleep latency test (MSLT) on the following day. Daytime sleepiness was also assessed by the Epworth sleepiness scale (ESS). The sleep recordings were visually scored according to standard criteria. The quantitative sleep EEG analysis was performed using a fast Fourier transform routine. The sleep parameters were compared between subjects with short and long MSLT sleep latencies (cut-off=10 min) and between subjects with low and high ESS scores (cut-off=6 points). RESULTS: Subjects with short MSLT sleep latencies showed a reduced theta EEG activity. There was no evidence of reduced synchronization of sleep EEG in subjects with high ESS scores. CONCLUSIONS: Moderately increased daytime sleepiness as indicated by MSLT sleep latency less than 10 min is accompanied by decreased power of theta activity during NREM sleep indicating a deficit of sleep EEG synchronization.

Rhythmic feet movements while falling asleep.

During the wake-sleep transition and sleep, diverse motor phenomena such as hypnagogic foot tremor may occur in the lower extremities. We investigated the relevance of this phenomenon in 375 consecutive subjects examined polysomnographically in a sleep disorders center. Rhythmic feet movements while falling asleep (RFM) were found in 28 subjects (7.5%). RFM occurred mostly as single, short series with a duration of between 10 and 15 seconds. They had a high night-to-night variability and were detected as rhythmic, oscillating movements of the whole foot or toes. Surface electromyographic (EMG) recordings displayed series of repetitive phasic bursts with a periodicity mostly between 1 and 2 per second. Single EMG burst duration varied between 300 and 700 msec. RFM at highest intensity occurred during presleep wakefulness, and usually persisted in sleep stages 1 and 2. RFM did not have a major sleep-disturbing effect in any of the affected subjects. Due to its high prevalence and the lack of a major sleep-disturbing effect, short series of RFM could be considered a quasiphysiological phenomenon. However, in more severe forms of RFM with evidence of a sleep-disturbing effect, RFM should be considered abnormal.

Normal plasma levels of orexin A (hypocretin-1) in narcoleptic patients.

Deficient orexin signaling has been shown to cause narcolepsy-like conditions in animals. In human narcolepsy, CSF levels of orexin A (hypocretin-1) were reported to be low in most cases. The authors measured CSF and plasma orexin A levels in patients with narcolepsy and in controls. Confirming earlier studies, they found CSF orexin A levels to be extremely low in patients with narcolepsy. However, plasma orexin A levels did not differ from those observed in controls. These results suggest that orexin deficiency in patients with narcolepsy is a phenomena restricted to the CNS.

Heart rate variability in patients with daytime sleepiness suspected of having sleep apnoea syndrome: a receiver-operating characteristic analysis.

1. Periodic breathing is known to be associated with cyclic fluctuations in heart rate. The purpose of this study was to evaluate the capability of spectral analysis of heart rate variability to identify episodes with periodic breathing in patients suspected of having sleep apnoea syndrome. 2. Forty-eight subjects complaining of chronic day-time sleepiness were studied using polysomnography and additional monitoring of Holter-ECG and synchronized pulse oximetry. The recordings were divided into 20 min episodes which were identified as recordings registered during normal breathing, periodic breathing, and periods of both normal and abnormal breathing. Power spectral analysis was performed on episodes which met the criteria of stationary of data (313 episodes with normal breathing, 264 episodes with continuous periodic breathing, 80 episodes with both normal and periodic breathing patterns). 3. The ability of parameters, derived from analysis of heart rate variability, to discriminate between episodes with normal and periodic breathing was assessed by receiver-operating characteristic analysis. 4. The spectral power component in the frequency range 0.01-0.07 Hz revealed the greatest accuracy for discriminating between normal and periodic breathing (area under the receiver-operating characteristic curve = 0.929; standard error = 0.009). The analysis of the episodes classified as false-positive at a given test sensitivity of 90% and a corresponding specificity of 77% revealed that half of these episodes had been recorded during transient central nervous arousal reactions related to periodic leg movements or heavy snoring. 5. We concluded that power spectral analysis of heart rate variability offers a possible means of identifying episodes of sleep-related breathing disorders or periodic leg movements. Therefore, analysis of heart rate variability may be a valuable additional diagnostic tool in patients undergoing Holter-ECG recording.

CHANGES IN TISSUE DEGRADATION MARKERS AND SUBJECTIVE REPORTS OF PAIN RESULTING FROM ECCENTRIC MUSCLE CONTRACTIONS.

The delayed onset of muscular soreness (DOMS) following a heavy eccentric exercise was studied with the aim to verify the "muscular structure" and the "connective tissue" theories explaining the development of DOMS. Die responses of creatine kinase (CK; "structural theory" marker) and hydroxyproline (OHP; "connective tissue theory" marker), as well as level and location of the perceived soreness, were determined following eccentric exercise. Plasma CK activity was elevated 48 and 72 h after the acentric exercise compared with the pre-exercise values, while OHP concentrations remained unchanged. Examination of pain location reports revealed two groups of responders (distal vs. mid-point muscle pain). Distal pain responders were found to have significantly higher post-exercise CK activity than mid-point pain responders, the OHP levels being alike. These findings are supportive of the "muscular structure" theory for DOMS development. However, the non-uniform location for DOMS pain confounds the overall data interpretation.

[Change in nCPAP pressure in repeated follow-up of patients with obstructive sleep apnea]. / Veränderung des nCPAP-Drucks bei wiederholten Kontrollen bei Patienten mit obstruktiver Schlafapnoe.

Ambulatory screening devices are gaining increasing acceptance for control measurements after CPAP therapy. This method has several disadvantages, however. For example, it cannot be determined, using ambulatory devices, whether a decrease in air pressure is possible. In addition, if a continuation of breathing problems exists, a full polygrafic recording is required. In repeated control studies it was determined if, and to what extent, air pressure could be altered. Results indicate that in up to 50% of the cases changes in pressure were needed. It is concluded, at least in at-risk patients or those with compliance problems, a polygrafic recording is necessary.

DR2-positive monozygotic twins discordant for narcolepsy.

Narcolepsy runs in families, and recent research has revealed the human leukocyte antigen (HLA) DR2 to be a genetic marker closely associated with the disease. But, as indicated by family studies, other factors contribute to the pathogenesis of narcolepsy. The investigation of monozygotic twins is the most specific research tool for distinguishing between a multigenetic and a multifactorial pathogenetic model. We present clinical and sleep polygraphic data from two pairs of monozygotic twins, and in addition, from some of their first-degree relatives. In both pairs only one twin suffered from the clinical symptoms of narcolepsy/cataplexy. Only in these subjects did night sleep recordings and a multiple sleep latency test reveal both multiple sleep onset rapid-eye-movement periods (SOREMPs) and short mean sleep onset latencies. However, in two of the asymptomatic, HLA DR2+ relatives, short mean sleep onset latencies during the multiple sleep latency test (MSLT) were observed, and one, HLA DR2- relative showed REM sleep two times during the MSLT. Our results strongly favor a multifactorial pathogenetic model for narcolepsy.

A study of the occurrence of HLA DR2 in 124 narcoleptics: clinical aspects.

The authors examined HLA antigens in 124 narcoleptics. In addition to narcolepsy, 122 patients suffered also from cataplexy. The two patients without cataplexy suffered also from sleep paralysis and hypnagogic hallucinations. These two symptoms were also present in many of the other patients. HLA group DR2 was found in 120 patients including all six symptomatic cases. In four patients HLA DR2 was not present. Two of these were fully pronounced narcolepsy-cataplexy cases whereas the two other did not suffer from cataplexy. Since several other cases with negative DR2 have already been published it is necessary to admit the existence of DR2-negative narcolepsy, albeit very rare. Among 5 patients with isolated sleep paralysis HLA DR2 was present in one familial and 1 sporadic case. The authors further discuss some aspects of the classification of narcolepsies in the light of recent HLA studies as well as their delimitation from idiopathic hypersomnia.

Rapid eye movements, muscle twitches and sawtooth waves in the sleep of narcoleptic patients and controls.

Seventeen unmedicated patients with narcolepsy-cataplexy and 17 age- and sex-matched controls were recorded polygraphically for 3 consecutive nights. Rapid eye movements (REMs), m. mentalis twitches and sawtooth waves in the EEG were visually scored. REM and twitch densities during REM sleep were significantly higher in the patients than in the controls. The distribution pattern of REMs and twitches was altered in the patients: twitch density peaked in the first REM period and density of REMs showed an even distribution across all the REM periods of the night. In the controls both REM and twitch density increased from the first to the second REM period. We therefore assume that in the narcoleptics phasic activity of REM sleep is disinhibited. Densities of REMs, twitches and sawtooth waves did not correlate with one another in patients and controls. They appear to be independently regulated. The REM periods of the patients contained 3 times as many waking epochs as those of the controls. This suggests that in narcolepsy the transition REM/waking is selectively facilitated. The REM/NREM ratio of twitch and sawtooth wave densities was the same in patients and controls.

Torsion of the spleen in a five-and-a-half-month-old infant.

In this report, we describe torsion of the spleen in a five-and-a-half-month-old infant, thus far the youngest reported patient in the literature. Celiac angiography and tuftsin determination confirmed the clinical impression that the pathology was confined to the spleen. The infant underwent a splenectomy and made an uneventful recovery.